Safety and Tolerability of Oral Islatravir Once Monthly as Pre-Exposure Prophylaxis in Cisgender Men and Transgender Women Who Have an Elevated Likelihood of HIV-1 Exposure: Results From the IMPOWER-24 Randomized Phase 3 Study
Key Points
The aim was to evaluate the safety and tolerability of oral islatravir as pre-exposure prophylaxis in specific populations.
Conducted a randomized Phase 3 trial (IMPOWER-24)
Included cisgender men and transgender women
Assessed safety and tolerability of monthly islatravir
Islatravir was well-tolerated overall
Decreases in total lymphocytes were noted with islatravir use
Primary efficacy objectives were not analyzed due to early study termination
Abstract
Islatravir qm was generally well-tolerated; decreases in total lymphocytes were observed with islatravir. Original primary efficacy objectives were not assessed due to early study stoppage.
اسأل الذكاء الاصطناعي
Like
Bookmark
Share
View Full Paper
اسأل الذكاء الاصطناعي
Like
Bookmark
Share
View Full Paper
Safety and Tolerability of Oral Islatravir Once Monthly as Pre-Exposure Prophylaxis in Cisgender Men and Transgender Women Who Have an Elevated Likelihood of HIV-1 Exposure: Results From the IMPOWER-24 Randomized Phase 3 Study | Synapse